Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome

Clinical Endocrinology

Volumn 70, Issue 2, 2009, Pages 233-237

  Cho, L W ^a,b   Kilpatrick, E S ^c   Keevil, B G ^d   Coady, A M ^c   Atkin, S L ^b  

^a Centre for Diabetes and Endocrinology   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

^c HULL ROYAL INFIRMARY   (United Kingdom)

^d WYTHENSHAWE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; INSULIN; METFORMIN; PIOGLITAZONE; TETRAHYDROLIPSTATIN;

ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HOMEOSTASIS; HORMONE BLOOD LEVEL; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; OUTPATIENT CARE; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTI-OBESITY AGENTS; BODY MASS INDEX; FEMALE; HUMANS; HYPERANDROGENISM; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LACTONES; METFORMIN; POLYCYSTIC OVARY SYNDROME; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 58549097078     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2008.03309.x     Document Type: Article

References (24)

1. Glueck, C.J., Papanna, R., Wang, P. et al. (2003) Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism, 52, 908 915.
2. Ehrmann, D.A., Sturis, J., Byrne, M.M. et al. (1995) Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. Journal of Clinical Investigation, 96, 520 527.
3. Jayagopal, V., Kilpatrick, E.S., Holding, S. et al. (2002) The biological variation of insulin resistance in polycystic ovarian syndrome. Journal of Clinical Endocrinology and Metabolism, 87, 1560 1562.
4. ESHRE/ASRM-Sponsored-PCOS-Consensus-Workshop-Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility, 81, 19 25.
5. Jayagopal, V., Kilpatrick, E.S., Holding, S. et al. (2005) Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. Journal of Clinical Endocrinology and Metabolism, 90, 729 733.
6. Moghetti, P., Castello, R., Negri, C. et al. (2000) Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. Journal of Clinical Endocrinology and Metabolism, 85, 139 146.
7. Matthews, D.R., Hosker, J.P., Rudenski, A.S. et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28, 412 419.
8. Fraser, C.G. Harris, E.K. (1989) Generation and application of data on biological variation in clinical chemistry. Critical Reviews in Clinical Laboratory Science, 27, 409 437.
9. Gowans, E.M. Fraser, C.G. (1988) Biological variation of serum and urine creatinine and creatinine clearance: ramifications for interpretation of results and patient care. Annals of Clinical Biochemistry, 25, 259 263.
10. Kocak, M., Caliskan, E., Simsir, C. et al. (2002) Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome. Fertility and Sterility, 77, 101 106.
11. Fleming, R., Hopkinson, Z.E., Wallace, A.M. et al. (2002) Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism, 87, 569 574.
12. Ng, E.H., Wat, N.M. Ho, P.C. (2001) Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial. Human Reproduction, 16, 1625 1631.
13. Pasquali, R., Gambineri, A., Biscotti, D. et al. (2000) Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 85, 2767 2774.
14. Morin-Papunen, L.C., Vauhkonen, I., Koivunen, R.M. et al. (2000) Endocrine and metabolic effects of metformin versus ethinyl estradiol- cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. Journal of Clinical Endocrinology and Metabolism, 85, 3161 3168.
15. Nestler, J.E. Jakubowicz, D.J. (1996) Decreases in ovarian cytochrome P450c17α activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. New England Journal of Medicine, 335, 617 623.
16. Velazquez, E.M., Mendoza, S., Hamer, T. et al. (1994) Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism, 43, 647 654.
17. Ortega-Gonzalez, C., Luna, S., Hernandez, L. et al. (2005) Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 90, 1360 1365.
18. Glueck, C.J., Moreira, A., Goldenberg, N. et al. (2003) Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Human Reproduction, 18, 1618 1625.
19. Romualdi, D., Guido, M., Ciampelli, M. et al. (2003) Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Human Reproduction, 18, 1210 1218.
20. Brettenthaler, N., De Geyter, C., Huber, P.R. et al. (2004) Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 89, 3835 3840.
21. Maciel, G.A., Soares Junior, J.M., Alves da Motta, E.L. et al. (2004) Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertility and Sterility, 81, 355 360.
22. Bonora, E., Targher, G., Alberiche, M. et al. (2000) Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care, 23, 57 63.
23. Mather, K.J., Hunt, A.E., Steinberg, H.O. et al. (2001) Repeatability characteristics of simple indices of insulin resistance: implications for research applications. Journal of Clinical Endocrinology and Metabolism, 86, 5457 5464.
24. Monnier, L., Mas, E., Ginet, C. et al. (2006) Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. Journal of the American Medical Association, 295, 1681 1687.